Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Global study decodes HIV drug resistance after dolutegravir failure

NCT ID NCT06285110

Knowledge-focused Sponsor: University of Bern Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at over 1,100 people with HIV whose dolutegravir-based treatment stopped working. Researchers collected blood samples to find drug-resistance mutations in the virus. The goal is to understand why some treatments fail and how to better manage HIV in the future.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this research could help doctors choose better HIV medications for people whose current treatment fails.
What could go wrong
This is an observational study, not a treatment trial. It only looks at what went wrong, not how to fix it. Results may not apply to all HIV subtypes or regions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

1,103 people

The number who actually took part.

Started

Jun 2022

Finished

Aug 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients routinely treated at the local HIV care clinics.

Ages

10 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged 18 years or older and adolescents (10-17 years) * On any DTG-based ART regimen * Who develop virologic failure (VF) defined as a VL \>1000 copies/mL (single or confirmed measurement), * and have signed the informed consent. Exclusion Criteria: * No Informed Consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

AIDS HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV

Contacts and locations

Locations

  • ACONDA Centre de Prise en Charge et de Formation (CePReF)

    Abidjan, Côte d’Ivoire

  • Centre de Traitement Ambulatoire

    Brazzaville, Republic of the Congo

  • Centre de Traitement Ambulatoire

    Pointe-Noire, Republic of the Congo

  • Centre for Infectious Disease Research Zambia (CIDRZ)

    Lusaka, Zambia

  • Centre médical de suivi des donneurs de sang, CNTS

    Abidjan, Côte d’Ivoire

  • Centro Medico Huesped

    Buenos Aires, Argentina

  • HIV-NAT/Thai Red Cross AIDS Research Center (TRCARC)

    Bangkok, Thailand

  • Hopital de Jour du Centre Hospitalier Universitaire (CHU Souro Sanou)

    Bobo-Dioulasso, Burkina Faso

  • Hospital Jamot

    Yaoundé, Cameroon

  • Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

    Mexico City, Mexico

  • Instituto Nacional de Infectiologia Evandro Chagas - Fiocruz

    Rio de Janeiro, Brazil

  • Lighthouse clinic

    Lilongwe, Malawi

  • Martin Preuss Centre

    Lilongwe, Malawi

  • Masaka Regional Referral Hospital / AHF Uganda Cares

    Masaka, Uganda

  • Mbarara University of Science and Technology / Mbarara ISS Clinic (MUST)

    Mbarara, Uganda

  • Moi University, AMPATH

    Eldoret, Kenya

  • National Centre for HIV/AIDS, Dermatology and STDs (NCHADS)

    Phnom Penh, Cambodia

  • National Institute for Medical Research (NIMR)

    Kisesa, Tanzania

  • Newlands Clinic

    Harare, Zimbabwe

  • Ramathibodi Hospital, Mahidol University

    Bangkok, Thailand

  • Regional Hospital Limbe

    Limbe, Cameroon

  • Research for Development, Einstein-Rwanda Research and Capacity Building Program

    Kigali, Rwanda

More trials for these conditions

Other studies related to the condition(s) this trial covers.